Cell Source Stock Beta
| CLCS Stock | USD 0.50 0.02 4.17% |
Cell Source fundamentals help investors to digest information that contributes to Cell Source's financial success or failures. It also enables traders to predict the movement of Cell OTC Stock. The fundamental analysis module provides a way to measure Cell Source's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cell Source otc stock.
Cell |
Cell Source OTC Stock Beta Analysis
Cell Source's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Cell Source Beta | -64.41 |
Most of Cell Source's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cell Source is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Cell Source has a Beta of -64.4132. This is 7589.91% lower than that of the Healthcare sector and notably lower than that of the Biotechnology industry. The beta for all United States stocks is notably higher than that of the company.
Cell Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cell Source's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Cell Source could also be used in its relative valuation, which is a method of valuing Cell Source by comparing valuation metrics of similar companies.Cell Source is currently under evaluation in beta category among its peers.
As returns on the market increase, returns on owning Cell Source are expected to decrease by larger amounts. On the other hand, during market turmoil, Cell Source is expected to outperform it.
Cell Fundamentals
| Return On Asset | -3.78 | |||
| Current Valuation | 59.65 M | |||
| Shares Outstanding | 35.25 M | |||
| Shares Owned By Insiders | 32.13 % | |||
| Price To Earning | (3.28) X | |||
| EBITDA | (4.11 M) | |||
| Net Income | (5.47 M) | |||
| Cash And Equivalents | 93.09 K | |||
| Total Debt | 6.5 M | |||
| Debt To Equity | (1.04) % | |||
| Current Ratio | 0.03 X | |||
| Book Value Per Share | (0.34) X | |||
| Cash Flow From Operations | (3.38 M) | |||
| Earnings Per Share | (0.20) X | |||
| Beta | -64.41 | |||
| Market Capitalization | 10.61 M | |||
| Total Asset | 313.77 K | |||
| Retained Earnings | (21.7 M) | |||
| Working Capital | (7.79 M) | |||
| Current Asset | 213.56 K | |||
| Current Liabilities | 8 M | |||
| Net Asset | 313.77 K |
About Cell Source Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cell Source's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cell Source using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cell Source based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Cell OTC Stock Analysis
When running Cell Source's price analysis, check to measure Cell Source's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cell Source is operating at the current time. Most of Cell Source's value examination focuses on studying past and present price action to predict the probability of Cell Source's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cell Source's price. Additionally, you may evaluate how the addition of Cell Source to your portfolios can decrease your overall portfolio volatility.